Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease

Panelists discuss how selecting an optimal combination of screening assessments for Alzheimer disease requires careful consideration of test sensitivity, specificity, accessibility, cost-effectiveness, implementation feasibility, and alignment with patient populations and health care resource constraints.

EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease

EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection

EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment

EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help

Now Viewing

EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease

EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease

EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas

EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations

EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy

EP: 10.Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations

EP: 11.Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease

EP: 12.Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers

EP: 13.Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy

EP: 14.Strategies for Clinicians When Developing Protocols for Managing ARIA

EP: 15.Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies

EP: 16.Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations

EP: 17.Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies

EP: 18.Final Thoughts Alzheimer Disease Care

Video content above is prompted by the following:

Related Videos

Related Content

Advertisement

July 23rd 2025

RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults

Cameron Santoro

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 22nd 2025

Total Joint Arthroplasty Outcomes Comparable for Patients With Osteoarthritis Regardless of Housing Status

Brooke McCormick

Researchers found no significant differences in surgical outcomes or follow-up between housed and unhoused patients with osteoarthritis undergoing total joint arthroplasty, suggesting the procedure is safe and effective regardless of housing status.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 18th 2025

Higher BMI Linked to Lower Mortality Rate, Fewer Complications in Non-CF Bronchiectasis

Brooke McCormick

Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while being underweight increases health complications.

July 18th 2025

Semaglutide, Tirzepatide Cut Dementia, Stroke Risk in Type 2 Diabetes

Pearl Steinzor

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Related Content

Advertisement

July 23rd 2025

RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults

Cameron Santoro

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 22nd 2025

Total Joint Arthroplasty Outcomes Comparable for Patients With Osteoarthritis Regardless of Housing Status

Brooke McCormick

Researchers found no significant differences in surgical outcomes or follow-up between housed and unhoused patients with osteoarthritis undergoing total joint arthroplasty, suggesting the procedure is safe and effective regardless of housing status.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 18th 2025

Higher BMI Linked to Lower Mortality Rate, Fewer Complications in Non-CF Bronchiectasis

Brooke McCormick

Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while being underweight increases health complications.

July 18th 2025

Semaglutide, Tirzepatide Cut Dementia, Stroke Risk in Type 2 Diabetes

Pearl Steinzor

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.